In this talk we will dive into 2 digital technologies: modular design and cloud. Both areas have the potential to accelerate the critical aspects of the facility of the future.
Explore how a stepwise approach for process characterization can help target the right experimental design and be tailored for different programs based on prior knowledge and experience.
With benefits across applications, nanoplasmids are designed to replace antiquated bacterial backbones, while eliminating antibiotic markers that can cause regulatory concerns.
To unlock the potential of your mRNA therapies and accelerate your development and manufacturing program, discover the benefits of a novel PCR-based mRNA drug substance manufacturing process.
Review data and evidence that demonstrates the benefits of an integrated approach to achieving critical end-user goals such as scalability, efficiency, sustainability, and optimized process economics.
Discover key upstream and downstream considerations for process development for RNA drug substance manufacturing and the parameters that need construct-specific optimization to increase yield and reduce impurities.
Nanoform CEO Edward Haeggstrom and Shawn Davies, head of drug delivery, biopharmaceuticals development, AstraZeneca, discuss the potential of nanoscale medicines and delivery devices.
Discover how revolutionary and environmentally sustainable nanoparticle technologies coupled with innovative formulation approaches can address drug solubility issues and add value for patients.
An industry expert shares about sustainable Oligo manufacturing approaches that can save time, cost, and resources – while improving purity, quality, and scalability of these promising therapeutics.
Examine the challenges CGT innovators face and how adhering to GMP requirements from early stage helps to ensure successful downstream applications from early clinical development to commercial phase.
Get the latest articles from Advancing RNA delivered to your inbox.